Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov:5:51-54.
doi: 10.1200/PO.20.00371.

Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge

Benjamin G Vincent  1 , Joseph D Szustakowski  2 , Parul Doshi  2 , Michael Mason  3 , Justin Guinney  3 , David P Carbone  4
Affiliations

Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge

Benjamin G Vincent et al. JCO Precis Oncol. 2021 Nov.
No abstract available

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Anti–PD-1 Response Prediction Challenge questions. NSCLC, non–small-cell lung cancer; OS, overall survival; PD, progressive disease; PD-1, programmed death-1; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. American Cancer Society : Facts & Figures 2020 Reports Largest One-Year Drop in Cancer Mortality. https://www.cancer.org/latest-news/facts-and-figures-2020.html
    1. Bristol Myers Squibb : OPDIVO® (Nivolumab) [package insert]. https://packageinserts.bms.com/pi/pi_opdivo.pdf
    1. Genentech Inc : TECENTRIQ® (Atezolizumab) [package insert]. https://www.gene.com/download/pdf/tecentriq_prescribing.pdf
    1. Merck & Co Inc : KEYTRUDA® (Pembrolizumab) [package insert]. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
    1. Sambi M, Bagheri L, Szewczuk MR: Current challenges in cancer immunotherapy: Multimodal approaches to improve efficacy and patient response rates. J Oncol 2019:4508794, 2019 - PMC - PubMed

Publication types